Information  X 
Enter a valid email address

Biocompatibles Intl. (BII)

  Print      Mail a friend

Thursday 22 May, 2003

Biocompatibles Intl.

Placing by Nomura

Biocompatibles International PLC
22 May 2003

22 May 2003

                  Biocompatibles International plc (LSE: BII)

            Placing by Nomura International of the J O Hambro stake

Biocompatibles International plc today announces that the 27% stake owned by J O
Hambro Capital Management, North Atlantic Smaller Companies Investment Trust and
Oryx International Growth Fund has been placed by Nomura International with a
range of investment institutions.

Sir Richard Needham, Chairman commented: "We are greatly encouraged by the
demand for this stake.  We presented our programmes and track record to our new
shareholders and they have responded positively."

"We are a world leader in the rapidly developing field of medical devices
incorporating drugs.  We have close partnerships with Abbott and Terumo and well
advanced programmes in drug eluting stents and embolisation devices.  We also
have a strong balance sheet."

James Hambro has indicated his intention to resign from the Board of
Biocompatibles.  Sir Richard Needham commented "On behalf of the Board, I would
like to thank Jamie for his constructive and helpful contributions."

                                    - Ends -


Biocompatibles International plc                Tel: +44 (0)1252 732732
Crispin Simon, Chief Executive
Swag Mukerji, Finance Director

Financial Dynamics                              Tel: +44 (0)20 7831 3113
David Yates

Notes to Editors

Biocompatibles International plc

Biocompatibles International plc is focused on the application of its polymer
technologies and drug elution expertise in medical devices and biomaterials that
improve patient quality of life.  The Company has incorporated its proprietary
Phosphorylcholine (PC) Technology into novel polymers which reduce the body's
response to foreign materials and have demonstrated potential as carriers for
therapeutic agents.

Biocompatibles has successfully commercialised PC Technology in a broad range of
products, including the BiodivYsio line of cardiovascular stents now owned by
Abbott Laboratories and the Proclear family of soft contact lenses, now a brand
of The Cooper Companies, Inc.

Biocompatibles is currently developing a range of products for use in
embolisation therapy to treat malignancies and benign tumours such as uterine
fibroids and continues to work in alliance with Abbott in the field of
drug-eluting stents.  Further Company information is available at

                      This information is provided by RNS
            The company news service from the London Stock Exchange

a d v e r t i s e m e n t